Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts
1997

Idoxifene vs Tamoxifen in Preventing Breast Cancer in Rats

Sample size: 272 publication Evidence: moderate

Author Information

Author(s): P Pace, M Jarman, D Phillips, A Hewer, J Bliss, RC Coombes

Primary Institution: Cancer Research Campaign Laboratories, Department of Medical Oncology, Charing Cross & Westminster Medical School

Hypothesis

Idoxifene is as effective as tamoxifen in preventing mammary carcinogenesis while causing fewer hepatic DNA adducts.

Conclusion

Idoxifene is as effective as tamoxifen in preventing mammary tumors in rats but results in significantly lower levels of DNA adducts in the liver.

Supporting Evidence

  • Idoxifene and tamoxifen both prevented tumor growth in treated rats.
  • Only 10% of vehicle-treated animals were alive and tumor-free after 24 weeks.
  • Idoxifene-treated animals had significantly lower levels of hepatic DNA adducts compared to tamoxifen-treated animals.

Takeaway

This study shows that idoxifene can help stop breast cancer in rats just like tamoxifen, but it doesn't hurt the liver as much.

Methodology

The study compared the effects of idoxifene and tamoxifen on mammary carcinogenesis in rats treated with MNU, measuring tumor development and hepatic DNA adduct formation.

Limitations

The study was conducted in rats, and results may not directly translate to humans.

Participant Demographics

In-bred virgin female Ludwig/Wistar/Olac rats, aged 45-55 days.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication